HUTCHINSON, Minn., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Hutchinson Technology Incorporated (Nasdaq:HTCH) today announced CE Mark and the market launch of the InSpectra™ StO2 Spot Check for use as a noninvasive, cost-effective tool to rapidly assess the tissue oxygenation of patients in circulatory distress. The product, which is targeted for use in emergency and critical care environments, is now available in countries that recognize the CE Mark. The company also has filed for marketing clearance of the product in the United States under the U.S. Food and Drug Administration's Premarket Notification, or 510(k), process.
About Hutchinson TechnologyHutchinson Technology is a global technology leader committed to creating value by developing solutions to critical customer problems. The company's BioMeasurement Division is focused on bringing new technologies and products to the market that provide information clinicians can use to improve the quality of health care and reduce costs. The company's Disk Drive Components Division is a leading worldwide supplier of suspension assemblies for disk drives. Cautionary Note Regarding Forward-Looking Statements This announcement may include forward-looking statements, including statements regarding marketing clearance by regulatory bodies and product commercialization and adoption. The company does not undertake to update its forward-looking statements. These statements involve risks and uncertainties. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of changes in changes in timely clearance by the appropriate regulatory bodies, market acceptance of new products and other factors described from time to time in the company's reports filed with the Securities and Exchange Commission.
CONTACT: Hutchinson Technology Inc. Investor Contact: Chuck Ives 320-587-1605 Media Contact: Connie Pautz 320-587-1823